Indiana University Research and Technology Corporation
发明人:
Kelley, Mark R.
申请号：
AU2017203131
公开号：
AU2017203131A1
申请日:
2017.05.11
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017203131A120170601.pdf#####ABSTRACT Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Apel/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the 5 use of agents to selectively inhibit the redox function of Apel/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Apel/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Apel/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a 10 component.
